Clinical Applications of Positron Emission Tomography/Computed Tomography Treatment Planning

Seminars in Nuclear Medicine

Volumn 38, Issue 2, 2008, Pages 137-140

  Macapinlac, Homer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' DEOXY 3' FLUOROTHYMIDINE F 18; TRACER; UNCLASSIFIED DRUG;

ACCURACY; ANGIOGENESIS; APOPTOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CELL PROLIFERATION; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; HEALTH CARE UTILIZATION; HUMAN; HYPOXIA; IMAGE ANALYSIS; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; REVIEW; RISK FACTOR; TREATMENT PLANNING; TUMOR LOCALIZATION; TUMOR VOLUME;

CARCINOMA, NON-SMALL-CELL LUNG; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGING, THREE-DIMENSIONAL; LUNG NEOPLASMS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 38549160207     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2007.11.005     Document Type: Review

References (41)

1. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
2. Verboom P., Van Tinteren H., Hoekstra O.S., et al. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging 30 (2003) 1444-1449
3. Lardinois D., Weder W., Hany T.F., et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348 (2003) 2500-2507
4. Verhagen A.F., Bootsma G.P., Tjan-Heijnen V.C., et al. FDG-PET in staging lung cancer: How does it change the algorithm?. Lung Cancer 44 (2004) 175-181
5. Reed C.E., Harpole D.H., Posther K.E., et al. Results of the American College of Surgeons Oncology Group Z0050 trial: The utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 126 (2003) 1943-1951
6. Vansteenkiste J.F., Stroobants S.G., De Leyn P.R., et al. Lymph node staging in nonsmall-cell lung cancer with FDG-PET scan: A prospective study on 690 lymph nodestations from 68 patients. J Clin Oncol 16 (1998) 2142-2149
7. Pieterman R.M., van Putten J.W., Meuzelaar J.J., et al. Preoperative staging of nonsmall-cell lung cancer with positron-emission tomography. N Engl J Med 343 (2000) 254-261
8. Pfister D.G., Johnson D.H., Azzoli C.G., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22 (2004) 330-353
9. Antoch G., Stattaus J., Nemat A.T., et al. Non-small cell lung cancer: Dual-modality PET/CT in preoperative staging. Radiology 229 (2003) 526-533
10. Erasmus J.J., Macapinlac H.A., and Swisher S.G. Positron emission tomography imaging in nonsmall-cell lung cancer. Cancer 110 (2007) 2155-2168
11. Yasufuku K., Nakajima T., Motoori K., et al. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest 130 (2006) 710-718
12. Hebert M.E., Lowe V.J., Hoffman J.M., et al. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: Preliminary findings. Am J Clin Oncol 19 (1996) 416-421
13. Kiffer J.D., Berlangieri S.U., Scott A.M., et al. The contribution of 18F-fluro-seoxyglucose positron emission tomography imaging to radiotherapy planning in lung cancer. Lung Cancer 19 (1998) 167-177
14. Nestle U., Walter K., Schmidt S., et al. 18F-deoxyglucose positron emission tomograpy (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 44 (1999) 593-597
15. Munley M.T., Marks L.B., Scarfone C., et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: Challenges and prospects. Lung Cancer 23 (1999) 105-114
16. Vanuytsel L.J., Vansteenkiste J.F., Stroobants S.G., et al. The impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 55 (2000) 317-324
17. Erdi Y.E., Rosenzweig K., Erdi A.K., et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 62 (2002) 51-60
18. Ciernik I.F., Dizendorf E., Baumert B.G., et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study. Int J Radiat Oncol Biol Phys 57 (2003) 853-863
19. Greco C., Rosenzweig K., Cascini G.L., et al. Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer 57 (2007) 125-134
20. Erdi Y.E., Rosenweig K., Erdi A.K., et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 62 (2002) 51-60
21. Erdi Y., Mawlawi O., Imbriaco M., et al. Volume determination for metastatic lung lesions by adaptive PET image thresholding. Cancer 80 (1997) 2505-2509
22. Bradley J., Thorstad W.L., Mutic S., et al. Impact of FDG-PET on radiation therapy volume delineation in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 59 (2004) 78-86
23. Biehl K.J., Kong F.M., and Dehdashti F. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: Is a single standardized uptake value threshold approach appropriate?. J Nucl Med 47 (2006) 1808-1812
24. Nehmeh S.A., Erdi Y.E., Ling C.C., et al. Effect of respiratory gating on quantifying PET images of lung cancer. J Nucl Med 43 (2002) 876-881
25. Pan T., Mawlawi O., Nemeh S.A., et al. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med 46 (2005) 1481-1487
26. Pan T., Mawlawi O., Luo D., et al. Attenuation correction of PET cardiac data with low-dose average CT in PET/CT. Med Phys 33 (2006) 3931-3938
27. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 49 (2005) 95-108
28. Klopp A.H., Chang J.Y., Tucker S.L., et al. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys 69 (2007) 1409-1416
29. Faria SL, Menard S, Devic S, et al: Impact of FDG-PET/CT on radiotherapy volume delineation in non-small-cell lung cancer and correlation of imaging stage with pathologic findings. Int J Radiat Oncol Biol Phys, in press
30. Shields A.F., Grierson J.R., Dohmen B.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 (1998) 1334-1336
31. Shields A.F. Positron emission tomography measurement of tumor metabolism and growth: Its expanding role in oncology. Mol Imaging Biol 8 (2006) 141-150
32. Yamamoto Y, Nishiyama Y, Kimura N, et al: Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer. Eur J Nucl Med Mol Imaging, in press
33. Yamamoto Y., Nishiyama Y., Ishikawa S., et al. Correlation of (18)F-FLT and (18)F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34 (2007) 1610-1616
34. Teicher B.A., Lazo J.S., and Sartorelli A.C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41 (1981) 73-81
35. Rice G.C., Hoy C., and Schimke R.T. Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc Natl Acad Sci USA 83 (1986) 5978-5982
36. Gagel B., Reinartz P., Demirel C., et al. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 6 (2006) 51
37. Cherk M.H., Foo S.S., Poon A.M., et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-fluoromisonidazole and 18F-FDG PET. J Nucl Med 47 (2006) 1921-1926
38. Lewis J.S., and Welch M.J. PET imaging of hypoxia. Q J Nucl Med 45 (2001) 183-188
39. Chao K.S., Bosch W.R., Mutic S., et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49 (2001) 1171-1182
40. Dehdashti F., Grigsby P.W., Mintun M.A., et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 55 (2003) 1233-1238
41. Dehdashti F., Mintun M.A., Lewis J.S., et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 30 (2003) 844-850